GlycoTech was founded in 1991 and remains today as one of the premier companies focusing on the biological functions and medical applications of glycoconjugates. The company has established its own research programs and has developed a large intellectual property portfolio. Through its catalog business, GlycoTech has also established one of the largest libraries of rare carbohydrate reagents and technologies worldwide. GlycoTech has maintained a corporate alliance with Novartis for the past six years to develop small molecule mimics of carbohydrate ligands as potent antagonists for the aberrant extravasation of lymphocytes from the bloodstream during transplantation-induced reperfusion injury. In addition, licensing agreements were recently established with Chiron Corporation for worldwide sales in cancer diagnostics using anti-carbohydrate tumor markers owned by GlycoTech.